CVS Caremark (CVS), a drugstore chain that competes with Rite Aid (RAD) and Walgreen (WAG), reported earnings for the fourth quarter on Thursday. The market wasn't taken by them. Looking at the extreme right side of the chart, it can be seen that the stock came under some pressure after the release. This afternoon, the shares are under further pressure: at the time of this writing, they were off by 1.1% to $32.55, with heavy volume backing the trade.

Does it sound like the company missed the estimate attached to it? No, that wasn't the problem. According to the Associated Press, adjusted profit came in at 80 cents per share, one penny ahead of the prediction.

Rite Aid's (RAD) sell-off Thursday was almost comical. Sometimes you've just got to laugh when a stock that's trading around a dollar suddenly drops over 13%. That's exactly what the drugstore's shares did by the end of the day's regular session. It finished at a quote of 95 cents. And, as you might expect, volume was pretty significant.

Who buys a stock like this? Clearly, someone braver than me. Adding this one to a portfolio is basically no different than playing the slots in Vegas. The one-year chart hasn't changed much since I discussed the company back in June; it still tells a tale of volatility and downward momentum. It's not a ride I'm willing to take.

CVS Caremark (CVS), a drugstore chain that competes with Rite-Aid Corporation (RAD), Walgreen Company (WAG), and Wal-Mart Stores, Inc. (WMT), is acting in a boring way this afternoon. My screen shows, at the time of this writing, the stock down 44 cents, or 1.2%, to $36.64.

That's not too bad for the kind of trading session we're having. I bet CVS would have been up today following its Q1 report had the market action been different. But the tape is the tape, you can do nothing about that. According to Bloomberg BusinessWeek, the company made, on an adjusted basis, 60 cents per share, which was two pennies ahead of estimates.

Last Friday, we learned the economy added 123,000 jobs, the most in three years. Investors everywhere are now waiting for the Dow to cross the 11,000 mark and hoping that the 6% added to the major indexes in March will happen once again in April as we enter earnings season.

Personally, I don't think Dow 11,000 really means anything. But I'll admit I'm pretty fired up about the upcoming first-quarter earnings season. Since the first quarter of 2009 was arguably the worst part of the recession, favorable year-over-year comparisons will lead to blowout results for most companies. In fact, I expect the S&P 500's operating earnings to be up almost 70% during the first quarter on average. With numbers like that, it's easy to imagine the market will post significant gains.

Here are some highlights from this past week's earnings coverage on BloggingStocks:

• Acuity Brands Inc. (AYI) Q2 results were essentially flat but an analyst's upgraded helped boost shares.
• Borders Group Inc. (BGP) reported strong Q4 earnings due to cost cutting but revenue continued to decline.
• Cal-Maine Foods Inc. (CALM) received an analyst's downgrade on valuation following release of its Q3 report.
• CarMax Inc. (KMX) rose to a new 52-week high following better-than-expected Q4 earnings and sales results.
• Charming Shoppes Inc. (CHRS) posted a smaller-than-expected Q4 net loss and said same-store sales declined.

Rite Aid (RAD) continues to be a stock that I want to avoid. I know it's risen a lot over the last year, but such price action doesn't sway me in this case.

You've got to be careful when a company reports a loss, even if that loss is narrower than what was reported in the comparable period. In the fiscal fourth quarter, Rite Aid lost 24 cents per share. Last year at this time, the red ink came out to $2.67 per share. Yes, this is a vast improvement; same thing happened in the third quarter back in December of last year.

Walgreen Company (WAG), a drugstore entity whose major competitors are CVS Caremark (CVS), Rite Aid (RAD), and Wal-Mart Stores, Inc. (WMT), reported second-quarter data earlier today; they weren't too thrilling, to be completely honest.

On a reported basis, net income increased three pennies to 68 cents per share. On an adjusted basis, earnings came out to 70 cents per share (this would be after adding back the two pennies dedicated to restructuring charges). Estimates called for 71 cents per share. Poor Walgreen just couldn't keep up with the analysts this time around.

CVS Caremark (CVS), which competes with Walgreen (WAG), Rite Aid (RAD), and Wal-Mart (WMT), posted fourth-quarter data on Monday. Sales increased 7%, and adjusted earnings per share from continuing operations (excluding, in addition, a penny per share relating to a tax benefit) came in at 78 cents -- good for a growth rate of over 11%. That bottom-line performance matched analyst projections, according to our earnings preview.

As we all know, matching expectations is sometimes the death of a stock. The market has no conscience when it comes to mercilessly punishing an equity for not going beyond the call of the analysts. However, CVS actually did pretty well yesterday, rising 5% by the end of the session; the move was backed by healthy volume.

Drugstore chain Rite Aid (RAD) reported Monday that its same-store sales fell 1.8% in December, marking the seventh consecutive month of declines. Same-store front-end sales dropped 2.3% for the period ended Dec. 26, while pharmacy sales contracted by 1.5%. Total sales pulled back 3% to $2.09 billion.

Pharmacy sales had been fairly resilient of late, but the decline in the most recent month was attributed to the introduction of a growing number of generic drugs. Additionally, the number of prescriptions filled on a same-store basis dropped by 0.2%.